Latest Stories
FreeGuest Editorial
At the 2026 Annual Meeting of the American Society of Clinical Oncology in Chicago, results from the phase III HARMONi-6 trial were presented at the plenary session and published simultaneously in The Lancet. The HARMONi-6 trial tested a novel bispecific antibody that engages PD-1 and VEGF (ivonescimab), given with platinum-doublet chemotherapy to patients with previously untreated advanced squamous non-small cell lung cancer.
Guest Editorial
Globally, about 18 million people will be diagnosed with cancer and approximately 10 million people will die from cancer this year. Between 30–50% of these cancer cases are potentially preventable today, a fact that highlights that prevention remains one of the most effective and cost-effective long-term strategies to reduce the global cancer burden.
